The 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT 2026) was grandly held in Boston, USA, from May 11 to 15 local time. Beijing Genecradle Therapeutics Co., Ltd. (hereinafter referred to as "Genecradle Therapeutics") unveiled the core achievements of its GC801 pipeline on the international stage. It presented the cutting-edge research entitledHigh-Activity IgG-Degrading Enzyme Variant M33 for AAV Gene Therapyvia a poster presentation, demonstrating to the global academic community the breakthrough progress of China's gene therapy in the field of AAV pre-existing antibody degradation.
ASGCT: A Bellwether for Global Gene Therapy
Founded in 1996, the American Society of Gene & Cell Therapy (ASGCT) is the world's largest non-profit medical organization dedicated to gene and cell therapy research. Committed to advancing the scientific, technological and clinical applications of gene and cell therapy, it stands as the most authoritative and credible institution in the global gene and cell therapy field.
As a premier event in the global gene therapy sector, the ASGCT Annual Meeting draws thousands of scientists, clinicians and industry leaders worldwide. Participants explore cutting-edge advances and future development directions of gene therapy, foster exchanges and cooperation among academia, industry and regulatory authorities, and drive innovation and development of the global gene and cell therapy industry.
Genecradle Highlight GC801: IdeS Enzyme Variant M33
The IdeS enzyme variant M33 from the GC801 pipeline presented at the conference is specifically developed to address the industry-wide pain point of pre-existing neutralizing immunity in AAV gene therapy. Research findings indicate that the novel IdeS variant M33 offers an effective solution to overcome the challenge of AAV pre-existing immunity. It features faster IgG cleavage kinetics and can rapidly eliminate over 95% of various AAV antibodies in vivo, with performance markedly superior to wild-type IdeS.
As a highly efficient enzyme candidate for breaking through immune barriers, M33 is expected to remove the clinical application restrictions caused by pre-existing antibodies, significantly expand the eligible population for AAV gene therapy, and reshape the clinical application paradigm of AAV gene therapies.
A Universal Immune Solution Benefiting Patients Across All AAV Therapy Indications
The IgG antibody clearance mechanism targeted by GC801 is independent of specific therapeutic genes and target organs. Theoretically, it can therefore serve as a universal preconditioning regimen applicable to all gene therapy scenarios that rely on AAV vectors and are hampered by pre-existing antibodies.
This means that for both indications approved for clinical trials (Spinal Muscular Atrophy, SMA) and other AAV gene therapy indications (such as Pompe disease, hemophilia, Wilson's disease, Duchenne Muscular Dystrophy, Fabry disease, etc.), GC801 can effectively clear pre-existing anti-AAV neutralizing antibodies in patients. It grants valuable treatment access to patients who were originally excluded from clinical trials and ineligible for therapy due to antibody positivity.
Meanwhile, the technology platform has universal applicability and can be extended to broader application scenarios, realizing the transition from "available to a few" to "accessible to the majority", and laying a critical technical foundation for the popularized development of the global gene therapy industry.